· After the transfer of approval authority, regulators can exercise more coherent management over the chain from sample collection and intra-hospital circulation to scientific use, preservation, and cross-border cooperation;
· The method for companies to make compliance judgments should shift from “article-by-article comparison” to “identifying trigger points along the business chain”;
· For CGT companies, the core of overseas compliance is “path design in advance”;
· The recognition of domestic entities under red-chip structures, overseas financing, and license transactions requires attention;
· For companies and research institutions whose core assets are patents, compliance and intellectual property management should be designed in an integrated manner.
Written by | Lily Wang, Violet Shan
On November 5, 2026, Order No. 16 of the National Health Commission published the revised Implementing Rules for the Regulations on the Administration of Human Genetic Resources (hereinafter referred to as the “2026 Rules”). It took effect on the date of publication, and the Rules published by the Ministry of Science and Technology on May 26, 2023 (hereinafter referred to as the “2023 Rules”) were simultaneously repealed.
Both versions have eight chapters, and the number of articles was reduced from 78 to 61. This change is not a simple deletion but the result of a systematic adjustment of the regulatory authority, regulatory logic, and institutional tools: the regulatory focus has shifted from “access control for scientific research projects” to “full-chain governance of healthcare,” and the institutional focus has shifted from “prior gatekeeping” to “combining prior gatekeeping with institutional self-governance.”
This article starts with the change in the regulatory authority, compares and summarizes the core institutional differences between the two versions of the Rules, highlights key compliance response points for companies, and on this basis further discusses the intellectual property implications of this revision for corporate patent layout, infringement risk monitoring, and technology transfer. Article citations in this article are based on the published texts of the two versions of the Rules; the article-by-article comparison in the appendix is not expanded here.
I. Change in the Regulatory Authority
Article 3 of the 2023 Rules clearly provided that the Ministry of Science and Technology was responsible for national human genetic resources investigation, administrative licensing, supervision and inspection, administrative penalties, and other management work; Article 4 of the 2026 Rules adjusts this responsibility to the National Health Commission, and at the provincial level, “provincial science and technology administrative departments” are correspondingly adjusted to “provincial competent departments for human genetic resources.”
The direct background of this adjustment is the transfer of management responsibilities after the reform of Party and state institutions, but if it is merely understood as “changing the department that stamps the document,” its substantive impact would likely be underestimated.
As the actual scenarios in which human genetic resources are generated, hospital diagnosis and treatment, clinical trials, sample collection, and preservation have long been under the daily supervision of the healthcare system. After the transfer of approval authority, regulators can embed administrative licensing into the scenarios where resources actually arise, relying on medical institutions’ ethics review systems, clinical research management systems, and daily supervision capabilities to exercise more coherent management over the chain from sample collection and intra-hospital circulation to scientific use, preservation, and cross-border cooperation.
II. Core Institutional Changes: Eight Key Differences
The core institutional differences between the two versions of the Rules can be summarized in the following table:
|
Institutional stage |
Key points of the 2023 Rules |
Key points of the 2026 Rules |
Substance of change |
|
Framework structure |
General requirements, administrative licensing and filing, supervision and inspection, administrative penalties |
Split by business chain into four chapters: collection, preservation, international cooperation, and material export and external provision of information; supervision/inspection and administrative penalties merged into “Services and Supervision” |
Structure closer to the business chain; fewer articles |
|
Collection licensing |
Threshold for large-scale population research: 3,000 cases; important pedigrees and specific regions referred to generally |
Threshold raised to 10,000 cases; important pedigrees and specific regions limited to officially published lists/catalogues; splitting and breaking into parts prohibited, with discovery channels listed such as supervision/inspection, petitions and reports, public opinion monitoring, and academic paper comparison; multicenter collection applied for by the lead unit |
Licensing resources concentrated on highly sensitive resources; anti-circumvention through prohibition of splitting and lead-unit responsibility |
|
Preservation licensing |
Preservation defined as “preserving legally sourced resources for future scientific research” |
Preservation limited to scientific research purposes; explicitly excludes storage primarily for clinical diagnosis/treatment and teaching with research as a secondary purpose, storage for production of marketed drugs/devices, and temporary storage after testing; application materials refined; records of source and use information required, open sharing mechanism required, annual report by January 31 each year |
Definition narrowed and boundaries clarified; continuous management obligations specified |
|
International cooperation |
Two scenarios for filing of marketing clinical trials; exploratory research required separate application for international cooperative scientific research approval |
Filing conditions consolidated; exploratory research no longer requires separate application/approval; new “same-day confirmation” mechanism for filings not involving information export; multicenter studies applied for by sponsor or lead unit; four types of written explanations for non-material changes (including cumulative total not exceeding 10% of approved quantity or 10 cases) |
Clearer pathways, reduced approval burden, more detailed change management |
|
External provision of information |
Prior report and information backup; relatively narrow exceptions |
Exceptions expanded to three types: use by both cooperating parties under an approved/filed cooperation with the recipient listed, use of already public information, and provision to overseas drug regulatory authorities for overseas marketing registration after filing; new simplified pathway: submission of data to the National Center for Bioinformation for paper publication or academic exchange deemed completion of prior report; security review clause not retained, only export control linkage retained |
Facilitation and expanded exceptions in parallel; security review returns to the Regulations and Biosecurity Law framework |
|
Material export |
Relatively brief provisions |
Clearly requires approval by the National Health Commission and lists six types of application materials; international cooperation involving material export may be listed together and approved jointly |
Procedures detailed; duplicate filings reduced |
|
Recognition of foreign entities |
Includes vague scenarios such as “holding less than 50% but able to control or exert significant influence” and “exerting significant influence through contractual arrangements” |
Narrowed to overseas organizations and institutions established, actually controlled, or indirectly holding 50% or more interests by overseas organizations or individuals; “actual control” still leaves room for interpretation |
Clearer criteria; joint ventures, VIE, and contractual control structures still require careful judgment |
|
Supervision and penalties |
Detailed provisions on supervision/inspection, administrative coercion, penalty hearings, legal review, case handling periods, etc. |
“Services and Supervision” chapter has 16 articles; penalty procedures follow the Provisions on the Procedures for Health Administrative Penalties; new emergency and fast-track approval mechanisms and accelerated approval arrangements for Hong Kong and Macao institutions |
Procedures aligned with the healthcare system; responsibility devolved to entity self-governance |
Overall, the legislative logic of the 2026 Rules is “thresholds raised in some areas and lowered in others; procedures simplified in some areas and complicated in others”: the scope and recognition criteria for licensing triggers are more focused, duplicate filings across stages are consolidated, and facilitation clauses and anti-circumvention clauses appear simultaneously. As a result, the method for companies to make compliance judgments should shift from “article-by-article comparison” to “identifying trigger points along the business chain.”
III. Impact on Corporate Compliance and Key Response Points
First, collection licensing strategies need to be reassessed.
The threshold for large-scale population research has been raised from 3,000 cases to 10,000 cases, and important pedigrees and specific regions are limited to officially published lists/catalogues. Companies conducting cohort studies, cross-sectional studies, and other activities should accurately determine whether a license is triggered; split collection is explicitly prohibited, and supervision discovery channels include academic paper comparison, so companies should not evade licensing through sub-centers or batch collection.
Second, management responsibility for multicenter research has increased.
Collection licenses are applied for by the lead unit, and international cooperative clinical trials are applied for or filed by the sponsor or lead unit; after obtaining approval or completing filing, they must strengthen management of participating units and collect ethics review and commitment letters and other materials. As the sponsor, a company cannot treat “having the approval in hand” as the endpoint; it should establish mechanisms for collecting, verifying, and retaining sub-center ethics review conclusions and original commitment letters, and maintain ledger-based management of participating units’ collection quantities and sample flows, to avoid compliance risks arising from inadequate management of participating units. Article 29 of the 2026 Rules continues the arrangement requiring both Chinese and foreign parties to jointly apply and make commitments; the Chinese entity’s commitment responsibility is not reduced by procedural simplification.
Third, the compliance boundary for preservation activities has narrowed.
Storage primarily for clinical diagnosis/treatment and teaching with research as a secondary purpose, storage for production of marketed drugs and medical devices, and temporary storage after laboratory testing as required by laws and regulations or agreed in clinical research protocols do not constitute preservation licensing matters; however, sample libraries intended for future scientific research still require preservation licensing and must fulfill annual reporting (submitted by January 31 each year, covering preservation, use, open sharing, and outcomes), open sharing, and complete source information recording obligations. Article 20 of the 2026 Rules also allows combined applications where preservation and international cooperative scientific research simultaneously involve collection, so companies can coordinate application pathways at the project initiation stage.
Fourth, international cooperative clinical trial pathways are clearer.
For trials aimed at marketing registration, exploratory research is integrated into the filing framework, and filings not involving information export apply the “same-day confirmation” mechanism; companies can make coordinated arrangements at the protocol design stage, but research involving information export, material export, or exceeding filing conditions must still follow the corresponding procedures.
Fifth, information export requires distinguishing purposes and pathways.
For paper publication or academic exchange, data may be submitted to the National Center for Bioinformation before formal publication or before the conference, which is deemed completion of the prior report; all three types of exceptions have strict prerequisites, and “submitting data” should not be simply equated with completion of all compliance obligations. Where important pedigrees, specific regions, or large-scale genomic data are involved, assessment should still be conducted in light of the Regulations and the Biosecurity Law.
Sixth, recognition of foreign partners requires more detailed equity and contract review.
Companies should review partners’ equity structures, contractual control arrangements, and actual control relationships to avoid affecting cooperation pathways because a partner is recognized as a foreign entity; Hong Kong and Macao institutions with actual control by domestic investors may refer to the provisions for Chinese entities when engaging in relevant activities, and companies with cooperation arrangements in the Guangdong-Hong Kong-Macao Greater Bay Area may pay attention to the institutional arrangements in Article 60.
Seventh, internal governance and change management have become ongoing requirements.
Legal representative responsibility, management system and ledger construction, and identification and reporting of changes after licensing/filing (application for changes for material changes, written explanations for non-material changes) should be incorporated into institutions’ daily governance.
Eighth, penalty procedures and supervision/inspection should be aligned with the healthcare system.
Companies need to pay attention to procedural rules for health administrative penalties, including notification, statements and defenses, and hearings, and should fully retain ethics review, informed consent, sample source, and use records to respond to supervision and inspection.
IV. CGT Companies’ Overseas Expansion Is Directly Affected
Cell and gene therapy (CGT) products are naturally and strongly linked to human genetic resources: autologous CAR-T, TIL, stem cell therapies, and gene-editing therapies involve the full process of patient cell collection, preparation of genetically modified materials, in vitro manipulation, and reinfusion, and the clinical stage is also accompanied by the generation and flow of large-scale gene sequencing data. The reconfiguration of collection, preservation, international cooperation, and export pathways under the 2026 Rules has a direct impact on the overseas architecture design of CGT companies, which can be understood from three levels:
(I) Reconfiguration of Overseas Pathways and Approval Frameworks
First, license-out alongside domestic clinical trials has become a mainstream overseas expansion model for CGT companies. For international cooperative clinical trials conducted in healthcare institutions for the purpose of overseas marketing registration, the filing framework applies, and the exploratory research portion no longer requires separate application for international cooperative scientific research approval, which is expected to accelerate early-stage clinical initiation; filings not involving information export also apply the “same-day confirmation” mechanism, further shortening the waiting window before initiation.
Second, multicenter, multi-region clinical trials (MRCTs) should coordinate approval pathways at the protocol design stage. Collection of materials in domestic healthcare institutions, and testing/analysis and residual material processing within the institution or by a domestic unit designated in the protocol, are key arrangements for satisfying filing conditions; where cross-border testing by central laboratories or export of samples for process development is involved, a separate material export license must be applied for. Among the six types of application materials, the international cooperation agreement and the residual sample processing agreement are precisely the compliance carriers for ownership clauses in license transactions and CDMO/CMO arrangements.
(II) Path Design for Cross-Border Data and Material Flows
First, submission of registration dossiers to overseas drug regulatory authorities may apply the three types of exceptions from separate reporting and backup for external provision of information, but the prerequisite is that the information has been listed in the international cooperative clinical trial application and filing has been completed. Sensitive information in the dossiers, such as gene sequencing data, vector sequences, and manufacturing process parameters, should be checked item by item against pathway prerequisites and should not be broadly packaged and analogized.
Second, sample and data flows in cross-border cooperation should be handled separately by type: sample export requires a material export license and clear arrangements for destruction or return of residual samples; return of patient follow-up data to an overseas sponsor constitutes external provision of information and requires assessment of whether prior reporting and backup obligations are triggered. The exception for use of already public information should not be expansively interpreted to cover unpublished patient datasets.
(III) Entity Recognition and IP Coordination Under Overseas Architectures
First, red-chip structures, overseas financing, and license transactions may change the recognition result for domestic entities. Overseas listing reorganizations or overseas partners’ shareholding crossing 50% or forming an actual control relationship may create a risk that a domestic CGT company is recognized as a foreign entity, thereby losing the qualification to independently collect and preserve resources and being able to use China’s human genetic resources only through cooperation. Companies should complete recognition assessments at the architecture design stage and preset response mechanisms for changes in entity qualification in agreements; for arrangements involving the Guangdong-Hong Kong-Macao Greater Bay Area, companies may use the institutional space under Article 60 for Hong Kong and Macao institutions with actual control by domestic investors to refer to Chinese entities.
Second, IP layout must be coordinated with the pace of overseas expansion. For inventions completed using domestic genetic resources, when entering the Patent Cooperation Treaty (PCT) and national phases, attention should be paid to increasingly strict genetic resource source disclosure requirements in jurisdictions such as the European Union and Japan; domestic collection, preservation, and ethics review records should be archived simultaneously as an evidence chain of source legality. License-out agreements should clearly specify the scope of authorization, territorial and field divisions, ownership of improvements, and benefit-sharing based on resource contributions, to prevent mismatch between resource access compliance and IP returns.
For CGT companies, the core of overseas compliance is “path design in advance”: at the stage of transaction structure and clinical trial protocol design, complete overall planning of approval pathways, data and material flows, entity qualification, and ownership arrangements, rather than remedying after the transaction is implemented.
V. Intellectual Property Management: Integrated Design with Compliance
While facilitating scientific research activities, the 2026 Rules reconstruct the compliance baseline for R&D activities related to genetic resources. For companies and research institutions whose core assets are patents, compliance and IP management should be designed in an integrated manner, which can be developed from three levels: patent layout, infringement and data risk monitoring, and technology transfer.
(I) Patent Layout: The Compliance Evidence Chain Is a Front-End Asset for Patent Rights Confirmation
First, the legality of the source of genetic resources directly affects patent application quality. Under Article 26 of the Patent Law, for inventions and creations completed using genetic resources, the direct source and original source of the genetic resources must be stated. Under the 2026 Rules, documents such as collection licenses, preservation licenses, informed consent forms, and ethics review certificates are precisely the core evidence chain for source legality and disclosure obligations. Companies should incorporate such compliance documents into pre-application file management, ensuring that every patent family relying on genetic resources can be traced back to lawful acquisition records, and avoiding source defects affecting patent stability or disclosure compliance in overseas applications.
Second, layout timing must be aligned with the timeline of academic disclosure. Article 40 of the 2026 Rules provides a simplified pathway for external provision of information for paper publication and academic exchange purposes, namely “submission of data is deemed completion of the prior report,” making publication of research outputs smoother. However, facilitation does not change the basic novelty rules of the Patent Law: formal publication of a paper or public disclosure at a conference may constitute self-disclosure that destroys the novelty of one’s own patent. Research teams should complete patentability assessment and patent applications before paper submission or academic presentations, making “patent layout before publication” a mandatory node in the R&D process.
Third, highly sensitive resources within the lists/catalogues correspond to a higher degree of caution in layout. Research outputs related to important pedigrees and specific regional resources (such as pathogenic loci, biomarkers, and drug targets) have high commercial value, but resource acquisition is constrained by list/catalogue management. Relevant patent layout should assess in advance the legality arrangements for resource acquisition (informed consent, benefit-sharing), and in foreign applications attention should be paid to source disclosure requirements under the Nagoya Protocol framework, preventing compliance breaks in rights confirmation and enforcement.
Fourth, protection methods should preferably combine “patents and trade secrets.” Genomic data and cohort information are research assets that can be reused over the long term, and not all are suitable for patent disclosure. Companies can, in light of the tiered management of external provision of information under the 2026 Rules, manage in layers technical solutions suitable for patent protection (methods, uses, detection reagents) and databases and algorithm models suitable for trade secret protection: obtain exclusive rights through patent disclosure, maintain secrecy through internal ledgers and access controls, and form a complementary protection combination. At the same time, the deletion of the independent security review procedure at the Rules level in the 2026 Rules does not mean that information export regulation has been relaxed; PCT applications and overseas licensing negotiations involving important pedigrees, specific regions, or large-scale genomic data still need to complete export compliance assessments under the Regulations and the Biosecurity Law, preventing the IP internationalization pathway itself from constituting a violation.
(II) Infringement and Data Risk Monitoring: The Trade Secret Defense Line Under Facilitation of Information Export
First, the expansion of information export exceptions means that the frequency of cross-border genomic data flows will rise. The three types of situations exempt from separate reporting and backup, as well as the paper data submission pathway, all involve the external flow of sensitive data. Companies should implement tiered management of partners and recipients, clarify data use limitations, confidentiality obligations, and liability for breach, prevent leakage of core genomic data and related trade secrets during cooperation and export, and avoid others using leaked data to preemptively lay out patents or develop competing products.
Second, the narrowing of recognition criteria for foreign entities changes rights boundaries and entity qualification. Foreign entities may not independently collect or preserve China’s human genetic resources and may use them only through cooperation. Changes in a partner’s equity structure (such as foreign shareholding crossing 50% or formation of an actual control relationship) may cause the cooperating entity to be recognized as a foreign entity, thereby affecting existing cooperation pathways, data use permissions, and even patent application rights arrangements. Companies should set trigger mechanisms and response clauses for changes in entity qualification in cooperation agreements and dynamically monitor changes in partners’ equity and control rights.
Third, academic paper comparison has become a regulatory discovery channel. Statements in papers regarding sample sources, collection quantities, and research scope should be consistent with license and filing records. Compliance retrospection of public outputs is a new risk point: companies should establish a compliance review mechanism before paper publication to prevent inconsistent descriptions in public texts from becoming the basis for regulatory verification or competitors’ claims of rights defects. In addition, companies should also pay attention to resource flow information reflected in partners’ and competitors’ published patents and papers as input for infringement monitoring and freedom-to-operate (FTO) analysis: when external entities密集 lay out patents overseas for inventions relying on China’s genetic resources, companies may verify their source disclosure and acquisition legality records and, where necessary, assert rights or seek invalidity leads based on source defects or ownership.
(III) Technology Transfer and Commercialization of Results: Fixing Ownership Through Agreements as the Hub
First, ownership clauses should be front-loaded to the application stage. International cooperation application materials already include documents such as international cooperation agreements and residual sample processing agreements; arrangements for IP ownership, ownership of subsequent improvements, cross-border implementation licenses, and benefit-sharing should be negotiated and finalized before application and written into agreements, avoiding ownership vacuums caused by “application first, negotiation later.” The patent application rights and mechanisms for exercising shared rights in Sino-foreign cooperative R&D outputs especially require clear agreement.
Second, preservation open sharing mechanisms should be linked with commercialization of results. The 2026 Rules require preservation entities to establish open sharing mechanisms, completely record source and use information, and report outcomes annually. Institutions can accordingly build a “resources—data—patents—products” commercialization ledger, linking sample open sharing with material transfer agreements (MTAs) and licensing authorizations: internally clarifying ownership of outputs generated by research groups using samples and distribution of commercialization returns; externally exporting outputs such as biomarker detection methods through licensing and cooperative development, enabling genetic resource providers to obtain reasonable benefit returns in commercialization while ensuring implementing certainty for users. For derivatives of clinical samples preserved by clinical institutions, a distinction should also be made between research use and product development use; the latter may trigger additional licensing and filing obligations.
Third, strengthened entity responsibility requires IP management to be incorporated into the governance system. The legal representative responsibility system and management ledger requirements provide an institutional interface for institutions to establish IP management systems related to genetic resources: clarifying the IP centralized department, ownership and disclosure plans at the project initiation stage, and output registration and patent application processes, so that compliance records directly support patent examination responses, technology transfer due diligence, and dispute response.
VI. Conclusion
From the Ministry of Science and Technology to the National Health Commission, the institutional focus of human genetic resources management is shifting from “access control for scientific research projects” to “full-chain governance of healthcare.” Through arrangements such as adjusting collection thresholds, narrowing the definition of preservation, expanding international cooperation filing, simplifying information export pathways, and strengthening entity responsibilities, the 2026 Rules have built a regulatory framework closer to the business chain and more reliant on institutional self-governance. For companies, the compliance focus is no longer just “whether an approval has been obtained,” but “whether an internal governance system commensurate with the scale of business has been established”; for IP-intensive companies, compliance documents are simultaneously the evidence chain for patent rights confirmation, the warning line for risk monitoring, and the ownership voucher for technology transfer. The ability to manage these three in a coordinated manner will become a new competitive advantage.
(This article is a comparative analysis based on public government texts and does not constitute legal advice. Specific project arrangements for human genetic resources compliance and intellectual property should be further assessed in light of project plans, cooperation structures, and the latest regulatory practice.)
Author biographies

Lily Wang, Founder and CEO of Nuozhong Heyi, mentor for science and technology innovation and entrepreneurship. She has 18 years of experience in biopharma patent consulting and has previously served as head of IP at Novartis, WuXi Biologics, Ascentage Pharma, and start-up biotechs. She specializes in full-lifecycle management of new drug patents, global layout, licensing transactions, and technology transfer. She holds a Bachelor of Pharmacy from Xiangya School of Medicine, a Master’s degree in Medicinal Chemistry from Shanghai Institute of Materia Medica, Chinese Academy of Sciences, a Juris Master (JM) degree from Fudan University, an EMBA degree in Excellence in Service from CEIBS, and an HEMBA degree from EHL Business School in Switzerland. She founded Nuozhong Heyi in 2023 and has served more than 20 pharmaceutical companies, funds, incubation platforms, and university research institutions, supporting innovative drugs’ global layout and overseas expansion.

Violet Shan, Data Privacy and AI Governance Compliance Consultant at Zhuowei Law Firm. She has 18 years of experience in in-house legal and DPO (Data Protection Officer) roles and has successively been responsible for privacy protection, data, and AI governance legal compliance at several multinational pharmaceutical and medical device companies and well-known consulting firms. She specializes in domestic and cross-border data compliance across the full lifecycle of biopharmaceuticals and medical devices, cross-border data compliance solutions, AI compliance, and strategic planning for data assetization. She has accumulated extensive practical experience in clinical trial data export, human genetic resources compliance, AI algorithm ethics and filing, and IPO data compliance review, and has supported multiple innovative pharmaceutical and medical device companies in completing global layout and capital market engagement.